Transferrin receptor 1 (TfR1) can mediate cell endocytosis and thus absorb nanoparticles that specifically bind to it, so it has become the target of many active targeted nanoparticles. Studies have shown that hepatoma cells have high expression of TfR1, which can be used as a key target for tumor therapy nano-drug delivery system. In vitro evaluation is an important part of TfR1 targeting nano-carriers. However, there are many kinds of liver cancer cell models, and there may be some differences in their TfR1 expression levels. Some common hepatoma cell lines, including HepG2, Hep3B, MHCC97-H and Huh-1, were selected to determine the expression of TfR1 at mRNA level and protein level. The affinity efficiency of transferrin (Tf) and transferrin nucleic acid aptamer (Tf-APT) to different cells were also investigated. Paclitaxel-loaded TfR1 targeted liposomes were prepared and their inhibitory effects on cell growth of different cell lines were investigated. The results show that there were differences in the expression of TfR1 in five hepatoma cell lines at mRNA level and protein level, as well as the sensitivity to paclitaxel-TfR1 targeted liposomes.